Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for LITS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2002. Start Trial.
Date Value
March 31, 2026 2.098M
December 31, 2025 0.569M
September 30, 2025 -100.00M
June 30, 2025 0.00
March 31, 2025 0.00
December 31, 2024 20.45M
September 30, 2024 14.70M
June 30, 2024 19.54M
March 31, 2024 0.122M
December 31, 2023 24.52M
September 30, 2023 4.957M
June 30, 2023 19.40M
March 31, 2023 10.02M
December 31, 2022 10.53M
September 30, 2022 13.74M
June 30, 2022 20.11M
March 31, 2022 15.16M
December 31, 2021 -43.37M
September 30, 2021 14.99M
June 30, 2021 9.988M
March 31, 2021 15.39M
December 31, 2020 -5.144M
September 30, 2020 4.476M
June 30, 2020 -85.05M
March 31, 2020 9.103M
Date Value
December 31, 2019 -35.32M
September 30, 2019 4.967M
June 30, 2019 9.955M
March 31, 2019 9.768M
December 31, 2018 -0.193M
September 30, 2018 4.788M
June 30, 2018 -59.43M
March 31, 2018 5.098M
December 31, 2017 4.963M
September 30, 2017 5.042M
June 30, 2017 -0.04M
March 31, 2017 -5.012M
December 31, 2016 5.008M
September 30, 2016 -10.03M
June 30, 2016 0.029M
March 31, 2016 5.002M
December 31, 2015 0.026M
September 30, 2015 4.915M
June 30, 2015 4.999M
March 31, 2015 4.99M
December 31, 2014 -30.04M
September 30, 2014 9.995M
June 30, 2014 -0.038M
March 31, 2014 -15.02M
December 31, 2013 -20.00M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
SELLAS Life Sciences Group, Inc. 0.00
ACADIA Pharmaceuticals, Inc. -8.529M
Alnylam Pharmaceuticals, Inc. -363.46M
Anika Therapeutics, Inc. -1.28M
Savara, Inc. 32.60M